Donald D. Mooney
Direktor/Vorstandsmitglied bei NOVX Systems, Inc.
Aktive Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Joseph Wolk | M | 57 | 26 Jahre | |
Tom Valis | M | - |
NOVX Systems, Inc.
NOVX Systems, Inc. Medical SpecialtiesHealth Technology NOVX Systems, Inc. develops drug screening solutions. Its products include PatientVu, PatientVu Pain and UDS Tests and Dips. The company was founded by Tino Alavie in March 2001 and is headquartered in Richmond Hill, Canada. | - |
Gordon D. Hull | M | - |
NOVX Systems, Inc.
NOVX Systems, Inc. Medical SpecialtiesHealth Technology NOVX Systems, Inc. develops drug screening solutions. Its products include PatientVu, PatientVu Pain and UDS Tests and Dips. The company was founded by Tino Alavie in March 2001 and is headquartered in Richmond Hill, Canada. | - |
James Thompson | M | - |
NOVX Systems, Inc.
NOVX Systems, Inc. Medical SpecialtiesHealth Technology NOVX Systems, Inc. develops drug screening solutions. Its products include PatientVu, PatientVu Pain and UDS Tests and Dips. The company was founded by Tino Alavie in March 2001 and is headquartered in Richmond Hill, Canada. | - |
Keith Beckley | M | - |
NOVX Systems, Inc.
NOVX Systems, Inc. Medical SpecialtiesHealth Technology NOVX Systems, Inc. develops drug screening solutions. Its products include PatientVu, PatientVu Pain and UDS Tests and Dips. The company was founded by Tino Alavie in March 2001 and is headquartered in Richmond Hill, Canada. | - |
Gavin Sword | M | - |
NOVX Systems, Inc.
NOVX Systems, Inc. Medical SpecialtiesHealth Technology NOVX Systems, Inc. develops drug screening solutions. Its products include PatientVu, PatientVu Pain and UDS Tests and Dips. The company was founded by Tino Alavie in March 2001 and is headquartered in Richmond Hill, Canada. | - |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Charles Harwood | M | 70 |
Quest Diagnostics Infectious Disease, Inc.
Quest Diagnostics Infectious Disease, Inc. Miscellaneous Commercial ServicesCommercial Services Quest Diagnostics Infectious Disease, Inc. provides diagnostic services. It offers anti infective surveillance and consultative services to the diagnosis, treatment, and management of infectious diseases. The company was founded in 1978 and is headquartered in Cypress, CA. | 4 Jahre |
Joseph Scodari | M | 71 | 9 Jahre | |
Tom Manion | M | 70 | 8 Jahre | |
Michael G. Gravett | M | - |
ProteoGenix, Inc.
ProteoGenix, Inc. Medical SpecialtiesHealth Technology ProteoGenix is the first and only company solely committed to developing minimally invasive diagnostics that address unmet medical needs and improve pregnancy and neonatal management and outcomes. By applying innovative proteomic and molecular technologies, ProteoGenix has quickly become a leader in developing powerful diagnostic tools that have the potential to dramatically change the future of pregnancy and neonatal management. In 2002, four leading researchers in the area of perinatology and neonatology joined together to create ProteoGenix, a company dedicated to solving the mysteries of preterm birth and the significant medical, emotional and economic consequences that prematurity has on their society. Their passion for improving pregnancy management and the outcomes associated with preterm birth, along with their clinical expertise and scientific acumen, led ProteoGenix to achieve a truly significant recent scientific discovery identification of The Proteomic Map of Pregnancy. The physicians and scientists that became ProteoGenix were the first to identify and characterize a fundamental map of the key biologic fluids in pregnancy and show how this landscape changes in important pregnancy-related disorders. This groundbreaking work has received several significant scientific awards, including Best Clinical Study at the 2007 annual meeting of the Society for Maternal-Fetal Medicine, and has been the topic of numerous peer-reviewed publications. ProteoGenix has also developed the unique capability to utilize sophisticated nucleic acid-based molecular microbiology techniques such as quantitative Polymerase Chain Reaction (PCR) and Pyrosequencing, specifically optimized for use in key maternal, fetal, neonatal biological fluids to detect infectious and path physiological diseases associated with pregnancy. | 10 Jahre |
Leo Mullin | M | 81 | 16 Jahre | |
Jack Goldstein | M | 77 | 11 Jahre | |
Nancy A. Hornbaker | F | - |
Chiron Diagnostics Corp.
Chiron Diagnostics Corp. Medical SpecialtiesHealth Technology Part of Bayer AG, Chiron Diagnostics Corp. is a company that develops medical diagnostic products. The company is based in East Walpole, MA. Chiron Diagnostics was acquired by Bayer AG from Chiron Corp. on November 30, 1998 for $1,100 million. | 5 Jahre |
Anthony Barnes | M | 69 |
Chiron Diagnostics Corp.
Chiron Diagnostics Corp. Medical SpecialtiesHealth Technology Part of Bayer AG, Chiron Diagnostics Corp. is a company that develops medical diagnostic products. The company is based in East Walpole, MA. Chiron Diagnostics was acquired by Bayer AG from Chiron Corp. on November 30, 1998 for $1,100 million. | 2 Jahre |
C. Douglas White | M | 62 |
Chiron Diagnostics Corp.
Chiron Diagnostics Corp. Medical SpecialtiesHealth Technology Part of Bayer AG, Chiron Diagnostics Corp. is a company that develops medical diagnostic products. The company is based in East Walpole, MA. Chiron Diagnostics was acquired by Bayer AG from Chiron Corp. on November 30, 1998 for $1,100 million. | 3 Jahre |
Daphne Jones | F | 67 | 12 Jahre | |
Scott Wilkinson | M | 59 | 1 Jahre | |
Mary C. Getz | M | - |
Quest Diagnostics Infectious Disease, Inc.
Quest Diagnostics Infectious Disease, Inc. Miscellaneous Commercial ServicesCommercial Services Quest Diagnostics Infectious Disease, Inc. provides diagnostic services. It offers anti infective surveillance and consultative services to the diagnosis, treatment, and management of infectious diseases. The company was founded in 1978 and is headquartered in Cypress, CA. | - |
Thomas H. Grove | M | 74 |
ProteoGenix, Inc.
ProteoGenix, Inc. Medical SpecialtiesHealth Technology ProteoGenix is the first and only company solely committed to developing minimally invasive diagnostics that address unmet medical needs and improve pregnancy and neonatal management and outcomes. By applying innovative proteomic and molecular technologies, ProteoGenix has quickly become a leader in developing powerful diagnostic tools that have the potential to dramatically change the future of pregnancy and neonatal management. In 2002, four leading researchers in the area of perinatology and neonatology joined together to create ProteoGenix, a company dedicated to solving the mysteries of preterm birth and the significant medical, emotional and economic consequences that prematurity has on their society. Their passion for improving pregnancy management and the outcomes associated with preterm birth, along with their clinical expertise and scientific acumen, led ProteoGenix to achieve a truly significant recent scientific discovery identification of The Proteomic Map of Pregnancy. The physicians and scientists that became ProteoGenix were the first to identify and characterize a fundamental map of the key biologic fluids in pregnancy and show how this landscape changes in important pregnancy-related disorders. This groundbreaking work has received several significant scientific awards, including Best Clinical Study at the 2007 annual meeting of the Society for Maternal-Fetal Medicine, and has been the topic of numerous peer-reviewed publications. ProteoGenix has also developed the unique capability to utilize sophisticated nucleic acid-based molecular microbiology techniques such as quantitative Polymerase Chain Reaction (PCR) and Pyrosequencing, specifically optimized for use in key maternal, fetal, neonatal biological fluids to detect infectious and path physiological diseases associated with pregnancy. | - |
John D. Soriano | M | 62 | - | |
Dariusz Robert Gorka | M | 59 | 1 Jahre | |
Cornelius Merlini | M | - | 10 Jahre | |
Jerry Chang | M | 65 | 8 Jahre | |
John Gordon Rowan Hurrell | M | 75 |
Quest Diagnostics Infectious Disease, Inc.
Quest Diagnostics Infectious Disease, Inc. Miscellaneous Commercial ServicesCommercial Services Quest Diagnostics Infectious Disease, Inc. provides diagnostic services. It offers anti infective surveillance and consultative services to the diagnosis, treatment, and management of infectious diseases. The company was founded in 1978 and is headquartered in Cypress, CA. | - |
Paulo Costa | M | 73 | 5 Jahre | |
Jordan M. Kramer | M | - |
ProteoGenix, Inc.
ProteoGenix, Inc. Medical SpecialtiesHealth Technology ProteoGenix is the first and only company solely committed to developing minimally invasive diagnostics that address unmet medical needs and improve pregnancy and neonatal management and outcomes. By applying innovative proteomic and molecular technologies, ProteoGenix has quickly become a leader in developing powerful diagnostic tools that have the potential to dramatically change the future of pregnancy and neonatal management. In 2002, four leading researchers in the area of perinatology and neonatology joined together to create ProteoGenix, a company dedicated to solving the mysteries of preterm birth and the significant medical, emotional and economic consequences that prematurity has on their society. Their passion for improving pregnancy management and the outcomes associated with preterm birth, along with their clinical expertise and scientific acumen, led ProteoGenix to achieve a truly significant recent scientific discovery identification of The Proteomic Map of Pregnancy. The physicians and scientists that became ProteoGenix were the first to identify and characterize a fundamental map of the key biologic fluids in pregnancy and show how this landscape changes in important pregnancy-related disorders. This groundbreaking work has received several significant scientific awards, including Best Clinical Study at the 2007 annual meeting of the Society for Maternal-Fetal Medicine, and has been the topic of numerous peer-reviewed publications. ProteoGenix has also developed the unique capability to utilize sophisticated nucleic acid-based molecular microbiology techniques such as quantitative Polymerase Chain Reaction (PCR) and Pyrosequencing, specifically optimized for use in key maternal, fetal, neonatal biological fluids to detect infectious and path physiological diseases associated with pregnancy. | - |
Kevin Mosher | M | - | 4 Jahre | |
Michelle Harrison | M | - | 3 Jahre | |
Hugues Pitre | M | - | 4 Jahre | |
Jenny Swain | F | - | - | |
Greg Harriman | M | - | 10 Jahre | |
Thomas Finnerty | M | 66 |
Chiron Diagnostics Corp.
Chiron Diagnostics Corp. Medical SpecialtiesHealth Technology Part of Bayer AG, Chiron Diagnostics Corp. is a company that develops medical diagnostic products. The company is based in East Walpole, MA. Chiron Diagnostics was acquired by Bayer AG from Chiron Corp. on November 30, 1998 for $1,100 million. | 9 Jahre |
Nancy Ondovik | F | - | 23 Jahre | |
Hugh G. Dineen | M | 55 | 15 Jahre | |
Patrick Brady | M | - | 18 Jahre | |
Jessica X. Shen | M | 60 | 16 Jahre | |
Pascale d’Arbonneau | F | - | 4 Jahre | |
Terry Dagnon | M | 62 | 2 Jahre | |
Sheri Dodd | F | 58 | 13 Jahre | |
Dave Carter | M | - | 2 Jahre | |
Michael Yang | M | 62 | - | |
Francis H. Barker | M | 93 | 16 Jahre | |
Melissa McLaughlin | F | - | 12 Jahre | |
Patricia Sandler | F | 55 | 9 Jahre | |
Elizabeth Anderson | F | 66 | 12 Jahre | |
Gregory Lee | M | 61 | 5 Jahre | |
Raphael S. Pascaud | M | 52 | 14 Jahre | |
Suresh Kumar | M | 69 | 5 Jahre | |
Charles Redding | M | - | - | |
Robert W. Boyce | M | - | 7 Jahre | |
David van Avermaete | M | 72 | 2 Jahre | |
Gerald Bruce | M | 68 | 15 Jahre | |
Rick Anderson | M | 63 | 9 Jahre | |
Robert Michael Savel | M | 56 | 8 Jahre | |
William Creech | M | 72 |
Chiron Diagnostics Corp.
Chiron Diagnostics Corp. Medical SpecialtiesHealth Technology Part of Bayer AG, Chiron Diagnostics Corp. is a company that develops medical diagnostic products. The company is based in East Walpole, MA. Chiron Diagnostics was acquired by Bayer AG from Chiron Corp. on November 30, 1998 for $1,100 million. | 3 Jahre |
Ivan Delevic | M | 59 | 4 Jahre | |
Patricia G. Christian | F | 63 | - | |
Jeffrey Moy | M | 63 |
Chiron Diagnostics Corp.
Chiron Diagnostics Corp. Medical SpecialtiesHealth Technology Part of Bayer AG, Chiron Diagnostics Corp. is a company that develops medical diagnostic products. The company is based in East Walpole, MA. Chiron Diagnostics was acquired by Bayer AG from Chiron Corp. on November 30, 1998 for $1,100 million. | 16 Jahre |
Richard S. Creager | M | 71 |
ProteoGenix, Inc.
ProteoGenix, Inc. Medical SpecialtiesHealth Technology ProteoGenix is the first and only company solely committed to developing minimally invasive diagnostics that address unmet medical needs and improve pregnancy and neonatal management and outcomes. By applying innovative proteomic and molecular technologies, ProteoGenix has quickly become a leader in developing powerful diagnostic tools that have the potential to dramatically change the future of pregnancy and neonatal management. In 2002, four leading researchers in the area of perinatology and neonatology joined together to create ProteoGenix, a company dedicated to solving the mysteries of preterm birth and the significant medical, emotional and economic consequences that prematurity has on their society. Their passion for improving pregnancy management and the outcomes associated with preterm birth, along with their clinical expertise and scientific acumen, led ProteoGenix to achieve a truly significant recent scientific discovery identification of The Proteomic Map of Pregnancy. The physicians and scientists that became ProteoGenix were the first to identify and characterize a fundamental map of the key biologic fluids in pregnancy and show how this landscape changes in important pregnancy-related disorders. This groundbreaking work has received several significant scientific awards, including Best Clinical Study at the 2007 annual meeting of the Society for Maternal-Fetal Medicine, and has been the topic of numerous peer-reviewed publications. ProteoGenix has also developed the unique capability to utilize sophisticated nucleic acid-based molecular microbiology techniques such as quantitative Polymerase Chain Reaction (PCR) and Pyrosequencing, specifically optimized for use in key maternal, fetal, neonatal biological fluids to detect infectious and path physiological diseases associated with pregnancy. | - |
Francois A. Menard | M | 64 | 8 Jahre | |
Andrew Dahlkemper | M | 57 | 4 Jahre | |
Glen A. Kashuba | M | 61 | 7 Jahre | |
Robert Kenneth Lally | M | 68 | 4 Jahre | |
Peter Pfreundschuh | M | 55 | 8 Jahre | |
James M. Callahan | M | 82 | - | |
Anthony Blair | M | 63 |
Chiron Diagnostics Corp.
Chiron Diagnostics Corp. Medical SpecialtiesHealth Technology Part of Bayer AG, Chiron Diagnostics Corp. is a company that develops medical diagnostic products. The company is based in East Walpole, MA. Chiron Diagnostics was acquired by Bayer AG from Chiron Corp. on November 30, 1998 for $1,100 million. | 9 Jahre |
James Walsh | M | - | 3 Jahre | |
Guus van Kesteren | M | 83 | 24 Jahre | |
Donald D. Solomon | M | 73 | 3 Jahre | |
Catherine Burzik | F | 73 | 1 Jahre | |
Rebecca Robertson | F | 63 |
Chiron Diagnostics Corp.
Chiron Diagnostics Corp. Medical SpecialtiesHealth Technology Part of Bayer AG, Chiron Diagnostics Corp. is a company that develops medical diagnostic products. The company is based in East Walpole, MA. Chiron Diagnostics was acquired by Bayer AG from Chiron Corp. on November 30, 1998 for $1,100 million. | 3 Jahre |
Robert DiTullio | M | 70 |
ProteoGenix, Inc.
ProteoGenix, Inc. Medical SpecialtiesHealth Technology ProteoGenix is the first and only company solely committed to developing minimally invasive diagnostics that address unmet medical needs and improve pregnancy and neonatal management and outcomes. By applying innovative proteomic and molecular technologies, ProteoGenix has quickly become a leader in developing powerful diagnostic tools that have the potential to dramatically change the future of pregnancy and neonatal management. In 2002, four leading researchers in the area of perinatology and neonatology joined together to create ProteoGenix, a company dedicated to solving the mysteries of preterm birth and the significant medical, emotional and economic consequences that prematurity has on their society. Their passion for improving pregnancy management and the outcomes associated with preterm birth, along with their clinical expertise and scientific acumen, led ProteoGenix to achieve a truly significant recent scientific discovery identification of The Proteomic Map of Pregnancy. The physicians and scientists that became ProteoGenix were the first to identify and characterize a fundamental map of the key biologic fluids in pregnancy and show how this landscape changes in important pregnancy-related disorders. This groundbreaking work has received several significant scientific awards, including Best Clinical Study at the 2007 annual meeting of the Society for Maternal-Fetal Medicine, and has been the topic of numerous peer-reviewed publications. ProteoGenix has also developed the unique capability to utilize sophisticated nucleic acid-based molecular microbiology techniques such as quantitative Polymerase Chain Reaction (PCR) and Pyrosequencing, specifically optimized for use in key maternal, fetal, neonatal biological fluids to detect infectious and path physiological diseases associated with pregnancy. | 2 Jahre |
Mark Guinan | M | 62 | 13 Jahre | |
M. Judah Folkman | M | - | 7 Jahre | |
David L. L. Levison | M | 64 |
ProteoGenix, Inc.
ProteoGenix, Inc. Medical SpecialtiesHealth Technology ProteoGenix is the first and only company solely committed to developing minimally invasive diagnostics that address unmet medical needs and improve pregnancy and neonatal management and outcomes. By applying innovative proteomic and molecular technologies, ProteoGenix has quickly become a leader in developing powerful diagnostic tools that have the potential to dramatically change the future of pregnancy and neonatal management. In 2002, four leading researchers in the area of perinatology and neonatology joined together to create ProteoGenix, a company dedicated to solving the mysteries of preterm birth and the significant medical, emotional and economic consequences that prematurity has on their society. Their passion for improving pregnancy management and the outcomes associated with preterm birth, along with their clinical expertise and scientific acumen, led ProteoGenix to achieve a truly significant recent scientific discovery identification of The Proteomic Map of Pregnancy. The physicians and scientists that became ProteoGenix were the first to identify and characterize a fundamental map of the key biologic fluids in pregnancy and show how this landscape changes in important pregnancy-related disorders. This groundbreaking work has received several significant scientific awards, including Best Clinical Study at the 2007 annual meeting of the Society for Maternal-Fetal Medicine, and has been the topic of numerous peer-reviewed publications. ProteoGenix has also developed the unique capability to utilize sophisticated nucleic acid-based molecular microbiology techniques such as quantitative Polymerase Chain Reaction (PCR) and Pyrosequencing, specifically optimized for use in key maternal, fetal, neonatal biological fluids to detect infectious and path physiological diseases associated with pregnancy. | - |
Laurence McCarthy | M | 79 |
Quest Diagnostics Infectious Disease, Inc.
Quest Diagnostics Infectious Disease, Inc. Miscellaneous Commercial ServicesCommercial Services Quest Diagnostics Infectious Disease, Inc. provides diagnostic services. It offers anti infective surveillance and consultative services to the diagnosis, treatment, and management of infectious diseases. The company was founded in 1978 and is headquartered in Cypress, CA. | 19 Jahre |
Robert G. Savage | M | 70 | 6 Jahre | |
Michael P. Whitman | M | 63 | 3 Jahre | |
David Burgstahler | M | 55 |
Quest Diagnostics Infectious Disease, Inc.
Quest Diagnostics Infectious Disease, Inc. Miscellaneous Commercial ServicesCommercial Services Quest Diagnostics Infectious Disease, Inc. provides diagnostic services. It offers anti infective surveillance and consultative services to the diagnosis, treatment, and management of infectious diseases. The company was founded in 1978 and is headquartered in Cypress, CA. | 5 Jahre |
Philippe Ozanian | M | 59 | 1 Jahre | |
Robert A. Medv | M | 58 | 5 Jahre | |
Fred Cohen | M | 67 |
ProteoGenix, Inc.
ProteoGenix, Inc. Medical SpecialtiesHealth Technology ProteoGenix is the first and only company solely committed to developing minimally invasive diagnostics that address unmet medical needs and improve pregnancy and neonatal management and outcomes. By applying innovative proteomic and molecular technologies, ProteoGenix has quickly become a leader in developing powerful diagnostic tools that have the potential to dramatically change the future of pregnancy and neonatal management. In 2002, four leading researchers in the area of perinatology and neonatology joined together to create ProteoGenix, a company dedicated to solving the mysteries of preterm birth and the significant medical, emotional and economic consequences that prematurity has on their society. Their passion for improving pregnancy management and the outcomes associated with preterm birth, along with their clinical expertise and scientific acumen, led ProteoGenix to achieve a truly significant recent scientific discovery identification of The Proteomic Map of Pregnancy. The physicians and scientists that became ProteoGenix were the first to identify and characterize a fundamental map of the key biologic fluids in pregnancy and show how this landscape changes in important pregnancy-related disorders. This groundbreaking work has received several significant scientific awards, including Best Clinical Study at the 2007 annual meeting of the Society for Maternal-Fetal Medicine, and has been the topic of numerous peer-reviewed publications. ProteoGenix has also developed the unique capability to utilize sophisticated nucleic acid-based molecular microbiology techniques such as quantitative Polymerase Chain Reaction (PCR) and Pyrosequencing, specifically optimized for use in key maternal, fetal, neonatal biological fluids to detect infectious and path physiological diseases associated with pregnancy. | - |
David N. Chernoff | M | - |
Chiron Diagnostics Corp.
Chiron Diagnostics Corp. Medical SpecialtiesHealth Technology Part of Bayer AG, Chiron Diagnostics Corp. is a company that develops medical diagnostic products. The company is based in East Walpole, MA. Chiron Diagnostics was acquired by Bayer AG from Chiron Corp. on November 30, 1998 for $1,100 million. | 10 Jahre |
Walter M. Narajowski | M | 71 |
Quest Diagnostics Infectious Disease, Inc.
Quest Diagnostics Infectious Disease, Inc. Miscellaneous Commercial ServicesCommercial Services Quest Diagnostics Infectious Disease, Inc. provides diagnostic services. It offers anti infective surveillance and consultative services to the diagnosis, treatment, and management of infectious diseases. The company was founded in 1978 and is headquartered in Cypress, CA. | 5 Jahre |
John Onopchenko | M | 66 | 10 Jahre | |
Henry B. Schacht | M | 89 | 8 Jahre | |
H. John Oechsle | M | 61 | 3 Jahre | |
David P. Holveck | M | 79 | - | |
Durlin E. Hickok | M | 75 |
ProteoGenix, Inc.
ProteoGenix, Inc. Medical SpecialtiesHealth Technology ProteoGenix is the first and only company solely committed to developing minimally invasive diagnostics that address unmet medical needs and improve pregnancy and neonatal management and outcomes. By applying innovative proteomic and molecular technologies, ProteoGenix has quickly become a leader in developing powerful diagnostic tools that have the potential to dramatically change the future of pregnancy and neonatal management. In 2002, four leading researchers in the area of perinatology and neonatology joined together to create ProteoGenix, a company dedicated to solving the mysteries of preterm birth and the significant medical, emotional and economic consequences that prematurity has on their society. Their passion for improving pregnancy management and the outcomes associated with preterm birth, along with their clinical expertise and scientific acumen, led ProteoGenix to achieve a truly significant recent scientific discovery identification of The Proteomic Map of Pregnancy. The physicians and scientists that became ProteoGenix were the first to identify and characterize a fundamental map of the key biologic fluids in pregnancy and show how this landscape changes in important pregnancy-related disorders. This groundbreaking work has received several significant scientific awards, including Best Clinical Study at the 2007 annual meeting of the Society for Maternal-Fetal Medicine, and has been the topic of numerous peer-reviewed publications. ProteoGenix has also developed the unique capability to utilize sophisticated nucleic acid-based molecular microbiology techniques such as quantitative Polymerase Chain Reaction (PCR) and Pyrosequencing, specifically optimized for use in key maternal, fetal, neonatal biological fluids to detect infectious and path physiological diseases associated with pregnancy. | - |
Vijay K. Lathi | M | 49 |
ProteoGenix, Inc.
ProteoGenix, Inc. Medical SpecialtiesHealth Technology ProteoGenix is the first and only company solely committed to developing minimally invasive diagnostics that address unmet medical needs and improve pregnancy and neonatal management and outcomes. By applying innovative proteomic and molecular technologies, ProteoGenix has quickly become a leader in developing powerful diagnostic tools that have the potential to dramatically change the future of pregnancy and neonatal management. In 2002, four leading researchers in the area of perinatology and neonatology joined together to create ProteoGenix, a company dedicated to solving the mysteries of preterm birth and the significant medical, emotional and economic consequences that prematurity has on their society. Their passion for improving pregnancy management and the outcomes associated with preterm birth, along with their clinical expertise and scientific acumen, led ProteoGenix to achieve a truly significant recent scientific discovery identification of The Proteomic Map of Pregnancy. The physicians and scientists that became ProteoGenix were the first to identify and characterize a fundamental map of the key biologic fluids in pregnancy and show how this landscape changes in important pregnancy-related disorders. This groundbreaking work has received several significant scientific awards, including Best Clinical Study at the 2007 annual meeting of the Society for Maternal-Fetal Medicine, and has been the topic of numerous peer-reviewed publications. ProteoGenix has also developed the unique capability to utilize sophisticated nucleic acid-based molecular microbiology techniques such as quantitative Polymerase Chain Reaction (PCR) and Pyrosequencing, specifically optimized for use in key maternal, fetal, neonatal biological fluids to detect infectious and path physiological diseases associated with pregnancy. | - |
Wendy Yarno | F | 68 | 1 Jahre | |
Richard J. Hernandez | M | 80 | 3 Jahre | |
Kevin Johnson | M | 69 |
Quest Diagnostics Infectious Disease, Inc.
Quest Diagnostics Infectious Disease, Inc. Miscellaneous Commercial ServicesCommercial Services Quest Diagnostics Infectious Disease, Inc. provides diagnostic services. It offers anti infective surveillance and consultative services to the diagnosis, treatment, and management of infectious diseases. The company was founded in 1978 and is headquartered in Cypress, CA. | 2 Jahre |
G. Steven Burrill | M | 79 |
ProteoGenix, Inc.
ProteoGenix, Inc. Medical SpecialtiesHealth Technology ProteoGenix is the first and only company solely committed to developing minimally invasive diagnostics that address unmet medical needs and improve pregnancy and neonatal management and outcomes. By applying innovative proteomic and molecular technologies, ProteoGenix has quickly become a leader in developing powerful diagnostic tools that have the potential to dramatically change the future of pregnancy and neonatal management. In 2002, four leading researchers in the area of perinatology and neonatology joined together to create ProteoGenix, a company dedicated to solving the mysteries of preterm birth and the significant medical, emotional and economic consequences that prematurity has on their society. Their passion for improving pregnancy management and the outcomes associated with preterm birth, along with their clinical expertise and scientific acumen, led ProteoGenix to achieve a truly significant recent scientific discovery identification of The Proteomic Map of Pregnancy. The physicians and scientists that became ProteoGenix were the first to identify and characterize a fundamental map of the key biologic fluids in pregnancy and show how this landscape changes in important pregnancy-related disorders. This groundbreaking work has received several significant scientific awards, including Best Clinical Study at the 2007 annual meeting of the Society for Maternal-Fetal Medicine, and has been the topic of numerous peer-reviewed publications. ProteoGenix has also developed the unique capability to utilize sophisticated nucleic acid-based molecular microbiology techniques such as quantitative Polymerase Chain Reaction (PCR) and Pyrosequencing, specifically optimized for use in key maternal, fetal, neonatal biological fluids to detect infectious and path physiological diseases associated with pregnancy. | 5 Jahre |
Clifton Chang | M | - | 17 Jahre |
Statistik
Land | Beziehungen | % des Gesamten |
---|---|---|
Vereinigte Staaten | 90 | 94,74% |
Kanada | 5 | 5,26% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Donald D. Mooney
- Persönliches Netzwerk